Independent Franchise Partners LLP Purchases 21,886,537 Shares of Kenvue Inc. $KVUE

Independent Franchise Partners LLP boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 233.4% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 31,265,574 shares of the company’s stock after buying an additional 21,886,537 shares during the period. Kenvue makes up about 4.4% of Independent Franchise Partners LLP’s investment portfolio, making the stock its 11th largest position. Independent Franchise Partners LLP’s holdings in Kenvue were worth $654,388,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Kenvue by 1.8% in the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock worth $4,881,844,000 after purchasing an additional 4,101,880 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Kenvue by 1.2% in the second quarter. Geode Capital Management LLC now owns 49,001,887 shares of the company’s stock valued at $1,021,267,000 after purchasing an additional 604,953 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Kenvue by 38.6% in the 2nd quarter. American Century Companies Inc. now owns 30,265,020 shares of the company’s stock valued at $633,447,000 after purchasing an additional 8,436,166 shares during the last quarter. Norges Bank acquired a new stake in shares of Kenvue during the 2nd quarter worth approximately $537,418,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in Kenvue by 2.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 25,606,238 shares of the company’s stock valued at $613,882,000 after acquiring an additional 633,461 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $16.85 on Wednesday. The firm has a market capitalization of $32.28 billion, a P/E ratio of 22.47 and a beta of 0.60. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $25.17. The stock has a 50 day moving average price of $16.06 and a two-hundred day moving average price of $19.44. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98.

Kenvue (NYSE:KVUE) last announced its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. The firm had revenue of $3.76 billion for the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The company’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.28 EPS. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. Equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 26th. Shareholders of record on Wednesday, November 12th were given a dividend of $0.2075 per share. This represents a $0.83 annualized dividend and a yield of 4.9%. The ex-dividend date was Wednesday, November 12th. Kenvue’s dividend payout ratio is presently 110.67%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on KVUE. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a research report on Tuesday, October 14th. JPMorgan Chase & Co. cut their price objective on shares of Kenvue from $24.00 to $21.00 and set an “overweight” rating for the company in a report on Friday, October 10th. Evercore ISI set a $18.00 price target on Kenvue in a research report on Tuesday, October 28th. Bank of America decreased their target price on shares of Kenvue from $25.00 to $21.00 and set a “buy” rating on the stock in a report on Wednesday, October 8th. Finally, Jefferies Financial Group reduced their price target on shares of Kenvue from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and thirteen have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $20.23.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.